|Assessment process complete
|For the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Reimbursement not recommended
|NCPE assessment re-commenced
|NCPE assessment completed
|NCPE assessment outcome
|Reimbursement not recommended.
Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab (Soliris®) for the treatment of PNH in the Irish healthcare setting.
The NCPE do not believe that eculizumab (Soliris®) is value for money for the treatment of patients with PNH in the Irish Healthcare setting